Full-Time

Lab Compliance Manager

Vaxcyte

Vaxcyte

501-1,000 employees

Develops broad-spectrum vaccines for bacterial infections

Compensation Overview

$153k - $178k/yr

+ Equity component

San Carlos, CA, USA

Hybrid

Minimum of 3 days per week onsite.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
FDA Regulations
Quality Assurance (QA)

Get referred to Vaxcyte

See people who can refer or advise you

Requirements
  • A Bachelor's degree in a life sciences discipline, specifically Chemistry, Biochemistry, Biology, or a related field, or an equivalent combination of education and relevant work experience.
  • At least 8 years of experience in a compliance, quality, analytical, or laboratory role within the biopharmaceutical, vaccine, or related life sciences industry.
  • Working knowledge of Good Manufacturing Practice and/or Good Laboratory Practice principles and their practical application in a laboratory setting, including the distinction between GMP policy and lab-level operational procedures.
  • Experience authoring or contributing to controlled documents such as standard operating procedures, work instructions, qualification protocols, or investigation reports in a regulated environment.
  • Familiarity with data integrity principles, including ALCOA+, and Good Documentation Practices, with the ability to apply them in daily laboratory operations.
  • Experience executing or supporting equipment qualification activities in a regulated analytical or quality control laboratory environment.
  • Ability to work effectively with Quality Assurance, Analytical Development scientists, and cross-functional teams.
  • Effective written and verbal communication skills, including the ability to translate compliance requirements into clear, practical laboratory procedures.
  • Prior experience in a people-management or mentorship capacity, or demonstrated readiness to take on direct management responsibilities.
Responsibilities
  • Directly manage the Sample Management Specialist and provide day-to-day oversight of sample receipt, logging, storage, distribution, and disposition activities to ensure compliance with approved standard operating procedures, chain-of-custody requirements, and Good Documentation Practices standards.
  • Support the Sample Management process by managing samples during periods of high sample volume.
  • Partner with Quality Assurance to translate established quality policies and procedures into Analytical Development laboratory-specific standard operating procedures, work instructions, and forms, and serve as the primary author of lab-level controlled documents with Quality Assurance review and approval.
  • Support implementation of laboratory quality processes, including change control, deviation management, out-of-specification and out-of-trend investigations, and corrective and preventive action, in alignment with Quality Assurance-approved frameworks and applicable regulatory expectations for Phase I/II programs.
  • Implement Quality Assurance-defined data integrity requirements within the Analytical Development laboratory and ensure staff adhere to ALCOA+ principles across paper-based and electronic records, including Benchling and instrument data acquisition software.
  • Maintain method qualification records and lifecycle tracking documentation, including qualification status, method changes, and requalification needs, ensuring records are complete and inspection-ready.
  • Ensure instrument equipment qualification activities, including installation qualification, operational qualification, and performance qualification, follow Quality Assurance-approved protocols; maintain calibration and preventive maintenance schedules; and partner with Facilities and Engineering to oversee Analytical Development equipment.
  • Ensure equipment logbooks and qualification records are maintained consistently with Good Documentation Practices and inspection-readiness expectations.
  • Partner with the Analytical Science and Technology group to ensure oversight of the receipt, qualification, storage, traceability, and controlled disposal of reference standards and critical reagents used in Analytical Development laboratory testing.
  • Coordinate and deliver role-based laboratory training in alignment with Quality Assurance-established training requirements, maintaining training records and qualification documentation for Analytical Development laboratory personnel.
  • Ensure Analytical Development laboratory documentation, records, and daily practices remain inspection-ready; support Quality Assurance during internal audits and regulatory inspections as the lab-level point of contact for compliance-related questions.
Desired Qualifications
  • Experience at a clinical-stage biopharmaceutical or vaccine company, ideally interfacing with both Quality Assurance and analytical laboratory functions.
  • Familiarity with Food and Drug Administration expectations for Phase I/II quality control or analytical laboratory operations supporting early clinical biologics or vaccine programs.
  • Experience with electronic laboratory or quality systems such as Benchling, laboratory information management systems, or comparable platforms.
  • Exposure to 21 CFR Part 11 and electronic records/electronic signatures compliance in a laboratory context.
  • Prior experience supporting internal audits or regulatory inspections.
  • Familiarity with International Council for Harmonisation guidelines relevant to analytical methods and early clinical development, including Q2, Q6, Q8, and Q10.

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • All three OPUS adult Phase 3 trials fully enrolled by August 2026, de-risking execution.
  • The FDA expanded VAX-31 Breakthrough Therapy designation in May 2025 to include pneumonia.
  • Thermo Fisher’s up-to-$1 billion agreement and Lonza manufacturing build support commercial readiness.

What critics are saying

  • VAX-31 OPUS-1 data shifted to October 2026, compressing launch timelines.
  • Q2 2026 burn reached $284.3 million, while cash funding depends on dilution.
  • Pfizer Prevnar 20 and Merck Capvaxive already control adult pneumococcal vaccination, threatening VAX-31 adoption.

What makes Vaxcyte unique

  • Vaxcyte’s XpressCF platform produced VAX-31, a 31-valent PCV, on September 10, 2026.
  • OPUS trials were finalized with FDA alignment for a planned BLA submission.
  • Thermo Fisher and Lonza manufacturing deals lock commercial capacity across U.S. and Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-4%

2 year growth

-1%
Yahoo Finance
Sep 8th, 2026
Vaxcyte CFO surrenders shares for tax, company holds $2.5B cash against $605M loss

Vaxcyte's president and CFO Andrew Guggenhime disposed of 2,705 shares according to a recent SEC filing. The transaction involved shares surrendered to satisfy tax withholding obligations on vested restricted stock units, not a discretionary sale. Guggenhime retains approximately 164,000 shares valued at $10.12 million based on 2 September's market close. His holdings consist of 102,000 shares held directly and 61,850 shares held indirectly through ALG 2025 Grat Holdings LLC. The clinical-stage biotechnology company held $2.51 billion in cash and investments at the end of June. However, Vaxcyte reported a six-month net loss of $604.9 million, with second-quarter operating expenses reaching $302.8 million, up from $226.2 million the previous year. Vaxcyte's lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine, is currently in clinical trials. The company has a market capitalisation of $9 billion.

Yahoo Finance
Sep 8th, 2026
Vaxcyte CEO sells shares for tax purposes as biotech burns $284M ahead of pivotal vaccine trial

Vaxcyte CEO Grant Pickering disposed of 6,289 shares of common stock in a non-discretionary transaction to cover tax withholding obligations from vesting restricted stock units, according to an SEC filing. The shares were valued at approximately $385,000 based on a weighted average sale price of $61.20. The California-based clinical-stage biotechnology company is developing VAX-31, a 31-strain pneumococcal vaccine. Vaxcyte expects topline data in the fourth quarter from OPUS-1, its pivotal Phase 3 trial testing VAX-31 against Pfizer's Prevnar 20 and Merck's Capvaxive in approximately 4,000 adults aged 50 and older. The company burned $284.3 million in the June quarter alone, with research and development spending up 38% year-over-year to $267.9 million. Vaxcyte holds $2.5 billion in cash.

Yahoo Finance
Sep 6th, 2026
Vaxcyte posts $284M Q2 loss as three Phase 3 vaccine trials complete enrolment

Vaxcyte reported second-quarter results showing a net loss of $284.3 million, nearly double the $166.6 million loss from a year earlier. The clinical-stage vaccine maker has fully enrolled three Phase 3 trials for its lead pneumococcal candidate VAX-31, with 6,191 adults dosed across the studies. Research and development spending rose to $267.9 million from $194.2 million, driven by manufacturing preparation and trial costs. The company held $2.5 billion in cash and investments as of 30 June. The first major data readout from the OPUS-1 trial, comparing VAX-31 against Prevnar 20 and Capvaxive, is expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 will follow in the first half of 2027. Hedge fund ownership declined from 57 to 47 funds, whilst short interest stands at 10% of the float.

Yahoo Finance
Sep 3rd, 2026
Vaxcyte appoints ex-Pfizer vaccines CMO, narrows VAX-31 Phase 3 data timeline to October

Vaxcyte has appointed Luis Jodar and David McAvoy as chief medical officer and chief legal officer, respectively. The clinical-stage vaccine innovation company also narrowed its guidance for topline data from the VAX-31 adult Phase 3 OPUS-1 trial, now expecting results by the end of October 2026. Jodar joins from Pfizer, where he spent 17 years, most recently as senior vice president and chief medical officer for vaccines and infectious diseases. He led clinical development and regulatory strategy for programmes including Prevnar 13 and Prevnar 20. McAvoy previously served as chief legal officer at Teva. The appointments come as Vaxcyte prepares for its planned Biologics Licence Application submission and potential launch of VAX-31.

Yahoo Finance
Jun 1st, 2026
Vaxcyte completes VAX-31 Phase 3 trial enrollment, shares rise 8.7%

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.